|
|||||
|
|
| VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs2108622和CYP2C19*2基因多态性对中国汉族房颤患者华法林维持剂量的影响 | |
| 引用本文： | 方素君,林玮玮,林荣芳,王长连. VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs2108622和CYP2C19*2基因多态性对中国汉族房颤患者华法林维持剂量的影响[J]. 中国现代应用药学, 2018, 35(9): 1379-1383 |
| 作者姓名： | 方素君 林玮玮 林荣芳 王长连 |
| 作者单位： | 莆田市第一医院药剂科, 福建 莆田 351100,福建医科大学附属第一医院药剂科, 福州 350005,福建医科大学附属第一医院药剂科, 福州 350005,福建医科大学附属第一医院药剂科, 福州 350005 |
| 基金项目： | 福建省教育厅中青年教师教育科研项目（JA14282） |
| 摘 要： | 目的 探讨VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs2108622和CYP2C19*2位点基因多态性对中国汉族房颤患者华法林维持剂量的影响。方法 收集107例服用华法林达维持剂量的汉族房颤患者的血样和临床相关资料，应用PCR-RFLP法检测VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs2108622和CYP2C19*2基因型，采用独立样本t检验分析基因型与华法林维持剂量的相关性。多元线性回归建立给药模型，探讨基因多态性对华法林维持剂量的影响。结果 VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs2108622基因多态性和患者年龄、体质量能解释45.2%的华法林维持剂量差异。CYP2C19*2基因多态性对本研究人群华法林维持剂量无影响。结论 VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs2108622基因多态性显著影响中国汉族房颤患者的华法林维持剂量。 |
| 关 键 词： | 华法林 维持剂量 VKORC1 CYP2C9 CYP2C19*2 CYP4F2 rs2108622 |
| 收稿时间： | 2017-10-21 |
| 修稿时间： | 2018-04-19 |
Relationship of VKORC1-3673G>A, CYP2C9*3, CYP4F2 rs2108622 and CYP2C19*2 Genetic Polymorphisms and Maintenance Warfarin Dose Requirement in Han-Chinese Patients with Atrial Fibrillation |
|
| FANG Sujun,LIN Weiwei,LIN Rongfang and WANG Changlian. Relationship of VKORC1-3673G>A, CYP2C9*3, CYP4F2 rs2108622 and CYP2C19*2 Genetic Polymorphisms and Maintenance Warfarin Dose Requirement in Han-Chinese Patients with Atrial Fibrillation[J]. The Chinese Journal of Modern Applied Pharmacy, 2018, 35(9): 1379-1383 | |
| Authors: | FANG Sujun LIN Weiwei LIN Rongfang WANG Changlian |
| Affiliation: | Department of Pharmacy, The First Hospital of Putian City, Putian 351100, China,Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China,Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China and Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China |
| Abstract: | OBJECTIVE To explore the influence of VKORC1-3673G>A, CYP2C9*3, CYP4F2 rs2108622, and CYP2C19*2 genetic polymorphism on maintenance warfarin dose in a Han-Chinese population with atrial fibrillation. METHODS Genetic polymorphisms were detected in 107 patients with atrial fibrillation receiving warfarin by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Independent-samples t-test was used to investigate the association between VKORC1-3673G>A, CYP2C9*3, CYP4F2 rs2108622, and CYP2C19*2 genetic polymorphisms and maintenance warfarin dose. Multiple linear regression analysis was used to investigate the contribution of genetic polymorphisms to maintenance warfarin dose. RESULTS VKORC1-3673G>A, CYP2C9*3, CYP4F2 rs2108622 genotypes and clinical characteristics (age, body weight) could account for 45.2% of the variance in the warfarin maintenance dose in patients with atrial fibrillation. No relationship was found between the maintenance warfarin dose and CYP2C19*2 genotype. CONCLUSION VKORC1-3673G>A, CYP2C9*3 and CYP4F2 rs2108622 genetic polymorphism are significantly affect the maintenance warfarin dose in Han-Chinese patients with atrial fibrillation. |
| Keywords: | warfarin maintenance warfarin dose VKORC1 CYP2C9 CYP2C19*2 CYP4F2 rs2108622 |
| 点击此处可从《中国现代应用药学》浏览原始摘要信息 | |
| 点击此处可从《中国现代应用药学》下载全文 | |